NCT02633436|UnknownDMC
Research on the Role of SLC1A5 in the Development of Esophageal Cancer
Research on the Role of the Amino Acid Transporter SLC1A5 in the Development of Esophageal Cancer
Loading search results
Research on the Role of the Amino Acid Transporter SLC1A5 in the Development of Esophageal Cancer
Sponsor study identifier
observational
100
1 country
2
Study Start
December 2015
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
July 2018
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
August 2018
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
To explore the significance of Solute Carrier Family 1 Member 5 (SLC1A5) in the occurrence of esophageal cancer, by comparing the expression of SLC1A5 between esophageal cancer tissues and adjacent tissues.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
August 2018
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
December 2015
Date type not reportedThis date has not been verified as actual or estimated.
December 6, 2015
Actual (reported)December 17, 2015
Actual (reported)July 2018
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
August 2018
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
optical density (ODs) of each slice by immunohistochemistry assay
For immunohistochemistry assay： Briefly, the samples will be cut into slices, which will be stained with standard steps. Finally, three high power fields will be randomly selected from each slice and the average optical density (OD) will be measured in each field.
within one year (plus or minus 1 month) after surgery
SLC1A5 expression detected by WesternBlot
within one year (plus or minus 1 month) after surgery
SLC1A5 expression of esophageal cancer tissues from patients
SLC1A5 expression of paired adjacent esophageal tissues from patients
To observe the expression of SLC1A5 by immunohistochemistry and WesternBlot analysis.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Patients with histologically proven esophageal cancer
Liuzhou Maternity and Child Healthcare Hospital
Liuzhou, Guangxi, 545000, China
The Fourth Affiliated Hospital of Guangxi Medical University
Liuzhou, Guangxi, 545000, China
Tissue specimens of esophageal cancer patients will be collected and stored in liquid nitrogen after operations
Xiangcheng Wei
Guangxi Medical University Institutional Review Board
First Submitted
December 6, 2015
First Posted
December 17, 2015
Study Start
December 2015
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
July 2018
Estimated (date passed)Radiation Dose Escalation in Esophageal Cancer
Contact the study team to confirm eligibility.
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
August 2018
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
August 12, 2016
Record last verified: 2016-08
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: